Literature DB >> 15695796

A paired-image radiation transport model for skeletal dosimetry.

Amish P Shah1, Wesley E Bolch, Didier A Rajon, Phillip W Patton, Derek W Jokisch.   

Abstract

UNLABELLED: Toxicity of the hematopoietically active bone marrow continues to be a primary limitation in radionuclide therapies of cancer. Improved techniques for patient-specific skeletal dosimetry are thus crucial to the development of dose-response relationships needed to optimize these therapies (i.e., avoid both marrow toxicity and tumor underdosing). Current clinical methods of skeletal dose assessment rely heavily on a single set of bone and marrow cavity chord-length distributions in which particle energy deposition is tracked within an infinite extent of trabecular spongiosa, with no allowance for particle escape to cortical bone. In the present study, we introduce a paired-image radiation transport (PIRT) model that can provide a more realistic 3-dimensional geometry for particle transport of the skeletal site at both microscopic and macroscopic levels of its histology.
METHODS: Ex vivo CT scans were acquired of the lumbar vertebra and right proximal femur excised from a 66-y male cadaver (body mass index, 22.7 kg m(-2)). For both skeletal sites, regions of trabecular spongiosa and cortical bone were identified and segmented. Physical sections of interior spongiosa were then taken and subjected to nuclear magnetic resonance (NMR) microscopy. Voxels within the resulting NMR microimages were segmented and labeled into regions of bone trabeculae, endosteum, active marrow, and inactive marrow. The PIRT methodology was then implemented within the EGSnrc radiation transport code, whereby electrons of various initial energies are simultaneously tracked within both the ex vivo CT macroimage and the NMR microimage of the skeletal site.
RESULTS: At electron initial energies greater than 50-200 keV, a divergence in absorbed fractions to active marrow is noted between PIRT model simulations and those estimated under infinite spongiosa transport techniques. Calculations of radionuclide S values under both methodologies imply that current chord-based models used in clinical skeletal dosimetry can overestimate dose to active bone marrow in these 2 skeletal sites by approximately 4%-23% for low-energy beta-emitters ((33)P, (169)Er, and (177)Lu), by approximately 4%-25% for intermediate-energy beta-emitters ((153)Sm, (186)Re, and (89)Sr), and by approximately 11%-30% for high-energy beta-emitters ((32)P, (188)Re, and (90)Y).
CONCLUSION: The PIRT methodology allows for detailed modeling of the 3D macrostructure of individual marrow-containing bones within the skeleton, thus permitting improved estimates of absorbed fractions and radionuclide S values for intermediate-to-high beta-emitters.

Entities:  

Mesh:

Year:  2005        PMID: 15695796

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

2.  An image-based skeletal dosimetry model for the ICRP reference adult male--internal electron sources.

Authors:  Matthew Hough; Perry Johnson; Didier Rajon; Derek Jokisch; Choonsik Lee; Wesley Bolch
Journal:  Phys Med Biol       Date:  2011-03-22       Impact factor: 3.609

3.  Response functions for computing absorbed dose to skeletal tissues from photon irradiation--an update.

Authors:  Perry B Johnson; Amir A Bahadori; Keith F Eckerman; Choonsik Lee; Wesley E Bolch
Journal:  Phys Med Biol       Date:  2011-03-22       Impact factor: 3.609

4.  MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Authors:  Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

5.  Evaluation of dual energy quantitative CT for determining the spatial distributions of red marrow and bone for dosimetry in internal emitter radiation therapy.

Authors:  Mitchell M Goodsitt; Apeksha Shenoy; Jincheng Shen; David Howard; Matthew J Schipper; Scott Wilderman; Emmanuel Christodoulou; Se Young Chun; Yuni K Dewaraja
Journal:  Med Phys       Date:  2014-05       Impact factor: 4.071

6.  Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer.

Authors:  Donika Plyku; Robert F Hobbs; Kevin Huang; Frank Atkins; Carlos Garcia; George Sgouros; Douglas Van Nostrand
Journal:  J Nucl Med       Date:  2017-01-19       Impact factor: 10.057

7.  Bone marrow dosimetry using 124I-PET.

Authors:  Jazmin Schwartz; John L Humm; Chaitanya R Divgi; Steven M Larson; Joseph A O'Donoghue
Journal:  J Nucl Med       Date:  2012-03-13       Impact factor: 10.057

8.  Investigation of effect of variations in bone fraction and red marrow cellularity on bone marrow dosimetry in radio-immunotherapy.

Authors:  S J Wilderman; P L Roberson; W E Bolch; Y K Dewaraja
Journal:  Phys Med Biol       Date:  2013-06-19       Impact factor: 3.609

9.  3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT.

Authors:  Astrid Gosewisch; Harun Ilhan; Sebastian Tattenberg; Andrea Mairani; Katia Parodi; Julia Brosch; Lena Kaiser; Franz Josef Gildehaus; Andrei Todica; Sibylle Ziegler; Peter Bartenstein; Guido Böning
Journal:  EJNMMI Res       Date:  2019-08-14       Impact factor: 3.138

Review 10.  Virtual clinical trials in medical imaging: a review.

Authors:  Ehsan Abadi; William P Segars; Benjamin M W Tsui; Paul E Kinahan; Nick Bottenus; Alejandro F Frangi; Andrew Maidment; Joseph Lo; Ehsan Samei
Journal:  J Med Imaging (Bellingham)       Date:  2020-04-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.